International Scholarly Research Notices / 2011 / Article / Tab 1

Research Article

Serum Natrium Determines Outcome of Treatment of Advanced GIST with Imatinib: A Retrospective Study of 80 Patients from a Single Institution

Table 1

Patient and treatment characteristics.

Imatinib n  = 80 (%)Sunitinib n  = 32 (%)

Sex
 Male51 (64)10 (31)
 Female29 (36)22 (69)

Age, years
 Median (years)6361
 Range30–8740–85

Performance status
 054 (68)24 (75)
 118 (22)6 (19)
 27 (9)1 (3)
 31 (1)1 (3)

Concomitant disease
 No45 (56)21 (66)
 Yes35 (44)11 (34)

Prior malignancy
 No72 (90)28 (88)
 Yes8 (10)4 (12)

Primary treatment
 Surgery49 (61)22 (69)
 No prior surgery31 (39)10 (31)

Start dose of imatinib/sunitinib
 800 mg/50 mg10 (13)10 (31)
 400 mg/37,5 mg69 (86)19 (60)
 200 mg/25 mg1 (1)3 (9)

Permanent reduction of start dose
 No61 (76)25 (78)
 Yes19 (24)7 (22)

Reason for reduction of start dose
 Haematological2 (11)
 Musculoskeletal2 (11)3 (43)
 Multisystem1 (5)
 Dermatological7 (37)3 (43)
 Gastrointestinal6 (31)
 Other1 (5)1 (14)

Response(a)
 CR3 (4)
 PR47 (59)13 (41)
 SD16 (20)13 (41)
 PD13 (16)3 (9)
 Death before evaluation1 (1)3 (9)

Progression(b)
 No26 (33)8 (25)
 Yes52 (65)19 (59)
 Not evaluable2 (2)5 (16)

Local treatment
 No40 (77)17 (89)
 Yes12 (23)2 (11)

(a)Best response at any time during treatment. CR: complete response, PR: partial response, SD: stable disease, PD: progression of disease.
(b)Progression at the time of evaluation.

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.